menu
About Us
Classes Of Business
HMO Reinsurance
Provider Excess Of Less
Medical Reinsurance
Employer Stop Loss
Client Captive Programs
Cell & Gene Therapy
Cost Containment
News
Contact Us
News
Vertex, CRISPR’s gene-editing therapy Casgevy wins early FDA nod to treat beta thalassemia
on
January 16, 2024
(updated January 19, 2024)
| Category:
News
Vertex, CRISPR’s gene-editing therapy Casgevy wins early FDA nod to treat beta thalassemia
Click here to download PDF
